The engineering and other scientific segment, representing 85% of net revenue, recorded 13% net revenue growth. The environmental and health segment, representing 15% of net revenue, grew net revenue 9%, driven by work evaluating chemicals’ effects on human health and the environment. He said Exponent expects to generate more than $100 million of free cash flow in the second half of 2026. Full-Year Outlook RaisedExponent raised its 2026 outlook and now expects net revenue growth of 9% to 10%, with EBITDA representing 27.8% to 28.1% of net revenue. For the third quarter, Exponent expects net revenue growth of 8% to 10% year over year and EBITDA margin of 28.0% to 28.5%.